Diaxonhit Stock Euronext Paris
Equities
FR0004054427
Biotechnology & Medical Research
Sales 2023 | 130M 140M | Sales 2024 * | 138M 149M | Capitalization | 148M 160M |
---|---|---|---|---|---|
Net income 2023 | 4M 4.31M | Net income 2024 * | 9M 9.69M | EV / Sales 2023 | 1.29 x |
Net Debt 2023 * | 8.8M 9.48M | Net cash position 2024 * | 9.9M 10.66M | EV / Sales 2024 * | 1 x |
P/E ratio 2023 |
38.3
x | P/E ratio 2024 * |
15.3
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 61.3% |
Managers | Title | Age | Since |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 17-06-18 |
Director of Finance/CFO | 43 | 22-09-30 | |
Cathie Marsais
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 17-06-18 |
Director/Board Member | 68 | 09-11-03 | |
Director/Board Member | 67 | 17-06-14 |
1st Jan change | Capi. | |
---|---|---|
+22.81% | 46.81B | |
+46.56% | 41.29B | |
-1.88% | 41.37B | |
-6.20% | 28.87B | |
+11.33% | 26.06B | |
-21.00% | 19.13B | |
-1.43% | 11.96B | |
+30.73% | 12.39B | |
-0.48% | 12.08B |